Briacell Therap (NASDAQ:BCTX) Short Interest Update

Briacell Therap (NASDAQ:BCTX) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 145,756 shares, an increase of 40.2% from the February 26th total of 103,944 shares. Approximately 2.0% of the shares of the company are sold short. Based on an average daily trading volume, of 273,289 shares, the short-interest ratio is presently 0.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Briacell Therap in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $320.00.

Briacell Therap Stock Down 3.6%

Briacell Therap stock opened at $3.75 on Friday. Briacell Therap has a 52-week low of $3.60 and a 52-week high of $98.20. The company has a market cap of $27.19 million, a P/E ratio of -0.16 and a beta of 1.46. The business has a 50-day simple moving average of $4.17 and a two-hundred day simple moving average of $7.87.

Briacell Therap (NASDAQ:BCTX) last issued its quarterly earnings data on Tuesday, March 10th. The company reported ($2.58) earnings per share for the quarter. Research analysts anticipate that Briacell Therap will post -2.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Briacell Therap stock. Flagship Harbor Advisors LLC purchased a new position in shares of Briacell Therap (NASDAQ:BCTX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,000 shares of the company’s stock, valued at approximately $28,000. Flagship Harbor Advisors LLC owned about 0.21% of Briacell Therap at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.42% of the company’s stock.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.